Mapping the effects of drugs on the immune system

Nature Biotechnology

Volumn 34, Issue 1, 2016, Pages 47-54

  Kidd, Brian A ^a   Wroblewska, Aleksandra ^a   Boland, Mary R ^b   Agudo, Judith ^a   Merad, Miriam ^a   Tatonetti, Nicholas P ^b   Brown, Brian D ^a   Dudley, Joel T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CELLS; CYTOLOGY; DIAGNOSIS; FORECASTING; IMMUNE SYSTEM;

CELL POPULATIONS; COMPUTATIONAL APPROACH; GENE SETS; IMMUNE CELLS; IN-VIVO EXPERIMENTS; PATIENT RECORD; SIDE EFFECT;

DRUG INTERACTIONS;

AZACITIDINE; BEPRIDIL; CELASTROL; CLOZAPINE; DAUNORUBICIN; DEPTROPINE; DEXVERAPAMIL; DOXORUBICIN; ETACRYNIC ACID; FLUSPIRILENE; GLICLAZIDE; HALOPERIDOL; IRINOTECAN; LOXAPINE; MEDRYSONE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NICLOSAMIDE; PERHEXILINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIMOZIDE; PRIMAQUINE; PUROMYCIN; PYRVINIUM EMBONATE; QUINOSTATIN; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; ELECTRONIC MEDICAL RECORD; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MEMORY T LYMPHOCYTE; MODEL; MONOCYTE; MOUSE; NATURAL KILLER T CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRE B LYMPHOCYTE; PRE T LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; DRUG EFFECTS; GENETIC TRANSCRIPTION;

ANIMALS; HUMANS; IMMUNE SYSTEM; MICE; TRANSCRIPTION, GENETIC;

EID: 84953775211     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3367     Document Type: Article

References (67)

1. Kuhn, M., Campillos, M., Letunic, I., Jensen, L.J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
2. Tatonetti, N.P., Ye, P.P., Daneshjou, R. & Altman, R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra131 (2012).
3. Beghi, E. & Shorvon, S. Antiepileptic drugs and the immune system. Epilepsia 52 (suppl. 3), 40-44 (2011).
4. Røge, R., Moller, B.K., Andersen, C.R., Correll, C.U. & Nielsen, J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr. Res. 140, 204-213 (2012).
5. Maloney, D.G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195 (1997).
6. Vogelsang, G.B. et al. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326, 1055-1058 (1992).
7. Fox, R.I. et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93, 198-208 (1999).
8. Vézina, C., Kudelski, A. & Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726 (1975).
9. Romano, A. & Caubet, J.C. Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J. Allergy Clin. Immunol. Pract. 2, 3-12 (2014).
10. Kim, Y.J. et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol. Res. 6, 156-162 (2014).
11. Sicherer, S.H. & Leung, D.Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2013. J. Allergy Clin. Immunol. 133, 324-334 (2014).
12. Alvir, J.M., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L. & Schaaf, J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329, 162-167 (1993).
13. Ward, K.E., Archambault, R. & Mersfelder, T.L. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. Am. J. Health Syst. Pharm. 67, 206-213 (2010).
14. Garratty, G. Drug-induced immune hemolytic anemia. Hematology (Am Soc Hematol Educ Program) 2009, 73-79 (2009).
15. Cipolletta, D. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549-553 (2012).
16. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
17. Walker, R.G. et al. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase. PLoS Negl. Trop. Dis. 5, e1033 (2011).
18. Emert-Sedlak, L.A. et al. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem. Biol. 20, 82-91 (2013).
19. Bellucci, R. et al. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J. Clin. Invest. 122, 2369-2383 (2012).
20. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
21. Dudley, J.T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
22. Jahchan, N.S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364-1377 (2013).
23. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
24. Heng, T.S., Painter, M.W. & Consortium, I.G. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091-1094 (2008).
25. Jojic, V. et al. Identification of transcriptional regulators in the mouse immune system. Nat. Immunol. 14, 633-643 (2013).
26. Benoist, C., Lanier, L., Merad, M., Mathis, D. & Immunological Genome, P. Consortium biology in immunology: the perspective from the Immunological Genome Project. Nat. Rev. Immunol. 12, 734-740 (2012).
27. Miller, J.C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888-899 (2012).
28. Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. USA 107, 14621-14626 (2010).
29. Iorio, F., Tagliaferri, R. & di Bernardo, D. Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol. 16, 241-251 (2009).
30. Zhang, X. & Young, H.A. PPAR and immune system-what do we know? Int. Immunopharmacol. 2, 1029-1044 (2002).
31. Lewis, J.D. et al. Rosiglitazone for active ulcerative colitis: a randomized placebocontrolled trial. Gastroenterology 134, 688-695 (2008).
32. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. & Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301 (2010).
33. Jagtap, P. & Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421-440 (2005).
34. Maugeri-Saccá, M., Bartucci, M. & De Maria, R. DNA damage repair pathways in cancer stem cells. Mol. Cancer Ther. 11, 1627-1636 (2012).
35. Johannessen, T.C., Bjerkvig, R. & Tysnes, B.B. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance? Cancer Treat. Rev. 34, 558-567 (2008).
36. Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540-1542 (2006).
37. Fagius, J., Osterman, P.O., Siden, A. & Wiholm, B.E. Guillain-Barre syndrome following zimeldine treatment. J. Neurol. Neurosurg. Psychiatry 48, 65-69 (1985).
38. Goh, K.-I. et al. The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685-8690 (2007).
39. Kolar, D. et al. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr. Dis. Treat. 4, 389-403 (2008).
40. Fisahn, A. et al. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 33, 615-624 (2002).
41. Summers, C. et al. Neutrophil kinetics in health and disease. Trends Immunol. 31, 318-324 (2010).
42. Fortunati, E., Kazemier, K.M., Grutters, J.C., Koenderman, L. & Van den Bosch, v.J. Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. Clin. Exp. Immunol. 155, 559-566 (2009).
43. Beyrau, M., Bodkin, J.V. & Nourshargh, S. Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity. Open Biol. 2, 120134 (2012).
44. Cherny, R.A. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (2001).
45. Grossi, C. et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 17, 423-440 (2009).
46. Qiu, P. et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29, 886-891 (2011).
47. Devi, S. et al. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. J. Exp. Med. 210, 2321-2336 (2013).
48. Robertson, A.L. et al. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci. Transl. Med. 6, 225ra229 (2014).
49. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 110, 3507-3512 (2013).
50. Lin, S. et al. Comparison of the transcriptional landscapes between human and mouse tissues. Proc. Natl. Acad. Sci. USA 111, 17224-17229 (2014).
51. Cheng, Y. et al. Principles of regulatory information conservation between mouse and human. Nature 515, 371-375 (2014).
52. Shay, T. et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc. Natl. Acad. Sci. USA 110, 2946-2951 (2013).
53. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011).
54. Stepan, A.F. et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24, 1345-1410 (2011).
55. Evans, D.C. & Baillie, T.A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Devel. 8, 44-50 (2005).
56. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
57. Nam, D. De-correlating expression in gene-set analysis. Bioinformatics 26, i511-i516 (2010).
58. Wu, D. & Smyth, G.K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).
59. Yaari, G., Bolen, C.R., Thakar, J. & Kleinstein, S.H. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. Nucleic Acids Res. 41, e170 (2013).
60. Rahmatallah, Y., Emmert-Streib, F. & Glazko, G. Gene Sets Net Correlations Analysis (GSNCA): a multivariate differential coexpression test for gene sets. Bioinformatics 30, 360-368 (2014).
61. Painter, M.W. et al. Transcriptomes of the B and T lineages compared by multiplatform microarray profiling. J. Immunol. 186, 3047-3057 (2011).
62. Knijnenburg, T., Wessels, L., Reinders, M. & Shmulevich, I. Fewer permutations, more accurate P-values. Bioinformatics 25, i161 (2009).
63. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57, 289-300 (1995).
64. Morgan, A.A., Khatri, P., Jones, R.H., Sarwal, M.M. & Butte, A.J. Comparison of multiplex meta analysis techniques for understanding the acute rejection of solid organ transplants. BMC Bioinformatics 11 (suppl. 9), S6 (2010).
65. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
66. Linderman, M.D. et al. CytoSPADE: high-performance analysis and visualization of high-dimensional cytometry data. Bioinformatics 28, 2400-2401 (2012).
67. Choi, B.Y. et al. Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. Neurobiol. Dis. 54, 382-391 (2013).